GT
BTAI icon

Glenmede Trust’s BioXcel Therapeutics BTAI Stock Holding History

Glenmede Trust’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-152
Closed -$105K – 1354
2020
Q3 		$105K Buy
152
+39
+35% +$29.3K ﹤0.01% 1155
2020
Q2 		$95K Buy
+113
New +$73.7K ﹤0.01% 1166

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Glenmede Trust's BTAI Position: Q4 2020 in Review

Glenmede Trust sold out of BioXcel Therapeutics (BTAI) in Q4 2020, closing a stake of 152 shares — an estimated $105K sold.

Glenmede Trust first reported a position in BTAI in Q2 2020 and held it in 2 quarters. The position peaked at $105K in Q3 2020. 117 funds tracked by Wall St. Rank hold BTAI as of Q4 2020.

  • Glenmede Trust reported no remaining BioXcel Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Glenmede Trust sold 152 BioXcel Therapeutics shares in Q4 2020, an estimated $105K.
  • Glenmede Trust first reported a position in BioXcel Therapeutics in Q2 2020 and held it in 2 quarters.
  • Glenmede Trust's BioXcel Therapeutics position peaked at $105K in Q3 2020.
  • 117 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.